Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y101D in metastatic or locally advanced solid tumors
NCT05028556Phase 1Completed
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Jul 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Y101D in solid tumor (5 arms), sponsored by Wuhan YZY Biopharma Co., Ltd. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events up to 6 months. Started Aug 2021; status: completed.
02
Drugs
Y101D
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05028556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028556.